dr. amin on rationale for checkmate-214 trial in rcc
Published 5 years ago • 159 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:06
dr. mckay discusses the checkmate-214 trial in rcc
-
1:32
dr. pal compares checkmate-214 and cabosun trials in rcc
-
1:17
dr. hammers on the checkmate-214 study for rcc
-
1:33
dr. pal on the checkmate-214 and cabosun studies in rcc
-
1:54
checkmate 214 trial in rcc updates
-
2:16
dr. amin on toxicities with immunotherapy/tki combinations in rcc
-
1:21
dr. powles on the 42-month follow-up data from the checkmate-214 trial in rcc
-
31:14
current treatment of advanced renal cell carcinoma, christian kollmannsberger, md
-
3:53
cabozantinib in combination with immunotherapy for advanced renal cell carcinoma
-
18:55
2021 west oncology app | new renal cell treatment options update
-
15:10
nccn guidelines update: impact of ipilimumab and nivolumab as preferred regimen for ccrcc
-
1:38
dr. mcdermott on an analysis of the checkmate-214 study in rcc
-
1:21
dr. hammers on the long-term benefits of the checkmate-214 study in rcc
-
2:13
dr. amin on next steps with immunotherapy in advanced rcc
-
3:07
checkmate-214: nivolumab/ipilimumab for mrcc?
-
2:30
checkmate 214 trial update
-
1:58
dr. plimack on significance of checkmate-025 trial in rcc
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
1:06
dr. agarwal on the checkmate-214 trial for kidney cancer
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:14
dr. choueiri on significance of checkmate-025 study for rcc
-
4:23
first-line therapy options for rcc: lessons from checkmate 214 and keynote-427